Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.15
-35.7%
$0.26
$0.12
$2.90
N/AN/A8,454 shs3,200 shs
PRENW
Prenetics Global
$0.01
+8.1%
$0.01
$0.01
$0.02
N/AN/A79,318 shs116 shs
SQLLW
SeqLL
$0.01
$0.01
$0.00
$0.11
N/AN/A9,750 shsN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$42.98
$42.86
$22.89
$52.23
$4.46B1.581.92 million shsN/A
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
-3.31%-25.51%-33.03%-51.82%-59.44%
PRENW
Prenetics Global
-14.00%-14.00%-20.37%-12.24%+14.67%
SQLLW
SeqLL
0.00%0.00%0.00%+228.50%+238.66%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/AN/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/AN/AN/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
PRENW
Prenetics Global
0.00
N/AN/AN/A
SQLLW
SeqLL
0.00
N/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$9.36MN/AN/AN/AN/AN/A
PRENW
Prenetics Global
$25.56MN/AN/AN/AN/AN/A
SQLLW
SeqLL
$1.18KN/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$5.39B0.83$6.72 per share6.40$33.96 per share1.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/A0.00N/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/A0.00N/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$266.50M$0.6962.29N/A1.31%8.63%3.66%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/A
SQLLW
SeqLL
N/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.77
1.20
1.20

Institutional Ownership

CompanyInstitutional Ownership
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
PRENW
Prenetics Global
N/A
SQLLW
SeqLL
N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
91.16%

Insider Ownership

CompanyInsider Ownership
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
PRENW
Prenetics Global
N/A
SQLLW
SeqLL
N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
10N/AN/ANot Optionable
PRENW
Prenetics Global
1N/AN/ANot Optionable
SQLLW
SeqLL
7N/AN/ANot Optionable
Syneos Health, Inc. stock logo
SYNH
Syneos Health
28,768103.72 million103.37 millionOptionable

Recent News About These Companies

Syneos Health makes senior hires
INC Research/inVentiv Health Becomes Syneos Health
Investment group will take Syneos Health private
Hayward Holdings, Inc. (HAYW)

Media Sentiment Over Time

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.15 -0.08 (-35.68%)
As of 04/29/2025 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Prenetics Global NASDAQ:PRENW

$0.0093 +0.00 (+8.14%)
As of 03:52 PM Eastern

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

SeqLL NASDAQ:SQLLW

$0.0066 0.00 (0.00%)
As of 04/29/2025

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Syneos Health stock logo

Syneos Health NASDAQ:SYNH

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.